COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021
Highlights: – Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021 – Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UK – Guy Goodwin appointed Chief Medical Officer and […]
Havn Life Sciences TO Present at Q3 Investor Summit Virtual Conference
Vancouver, British Columbia–(Newsfile Corp. – August 11, 2021) – Havn Life Sciences Inc. (CSE: HAVN ) (OTC Pink: HAVLF ) (FSE: 5NP ) (the “Company” or “Havn Life”), a biotechnology company developing natural health products and innovative therapies to support brain health and enhance the capabilities of the mind today announced that it will be presenting at the upcoming Q3 Investor Summit […]
Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research
Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that Silo’s joint venture partner, ZYLO Therapeutics, completed its first inspection with the SC Board of Pharmacy and will move forward with the Department of Health and Environmental Control. Eric Weisblum, CEO of Silo Pharma stated […]
